IDH2 and central nervous system cancer: Despite the fact that IDH mutations appear early in gliomagenesis [44], it remains unclear whether they initiate a less aggressive pathway to tumor development in comparison to IDH-wildtype gliomas [45] or they represent a tumor-suppressive factor that counterbalances glioma tumorigenesis and progression [46].